| **Overview** | **Status** | **Green** |
| --- | --- | --- |
| Key milestones within this reporting period include:   * The 1:200 design was approved by the Senior User Group on 10 June 2019. * Accommodation Options Paper for pharmacy and medical physics have been approved by the Senior User Group. | | |

|  |  |  |
| --- | --- | --- |
| **Progress Summary** | **Status** | **Green** |
| **Programme Update**  Kier have produced a high level programme whichaligns completion with the approved Initial Agreement (IA) date of end 2021. This will include other identified Work Task Orders (WTOs) on refurbishment of areas of the existing building.    **Commercial Summary**   * Fees agreed for Stage 1. * Advisor fees for Stage 1 agreed. * Stage 1 and Stage 2 contracts issued for comment.   **Design Status**  The 1:500 design was approved by the Senior User Group on 29 April 2019.  The 1:200 design was approved by the Senior User Group on 10 June 2019.  Work stream reviews of the 1:50 design are underway.  **Statutory Approval Status**  A series of meetings has been established with West Dunbartonshire Council (WDC), Kier and NHS Golden Jubilee to include Planning, Building Control, Environmental Heath and Transport to support future applications. These meetings will run until the end of July 2019.  **Site Investigation Works**  Site investigation works were carried out on site during May 2019. The full results will be issued following laboratory tests.  **Outline Business Case**  Work on drafting the Outline Business Case (OBC) continues alongside the design development work.  An action plan has been developed and will be shared with the Business Case Development and Assurance Group.  **Clinical Work stream group update**   * Workforce requirements for Phase 2 have been developed. This includes nursing, medical and all clinical and non-clinical support services. Some areas will require further review as the design process develops. * Work to understand the impact of the reduction in orthopaedic plain film demand (due to change in post-operative follow up regime) is complete. There has however been a delay in progressing the write up of the radiology plain film paper to assess the risks / benefits of co-locating the plain film service with outpatients. This is primarily due to the increased pace of the Phase 2 design development. The paper will be complete in August to inform the decision and any subsequent OBC costs. * Accommodation Options Paper for pharmacy and medical physics have been approved by the Senior User Group.   **Key Risks and Mitigation**  A risk and benefits workshop was held on 30 April 2019 to review the risk register risks noted at IA stage and agree the high level key benefits that will be realised through the project. | | |
| **Programme Budget** | **Status** | **Green** |
| A full update is provided within the Cost Control Report – June 2019. | | |
| **Issues Affecting the Programme** | **Status** | **Amber** |
| Provision of Consultant Microbiologist programme input. This has been raised with the National Elective Centre Programme Board and the possibility of a national resource being made available is being investigated. | | |
| **Communications and Stakeholder Engagement** | **Status** | **Green** |
| Attendance of programme team at cross divisional meetings to update on progress.  Programme updates for staff at Continuing Medical Education sessions and staff meetings.  Expansion updates for final year Allied Health Professions and Nursing students. | | |
| **Key Tasks for between now and next reporting period** | | |
| Key tasks for the forthcoming period include:   * Completion and signing of Stage 1 and 2 contracts. * Finalise the plain film imaging requirements for Phase 2 – taking into account the impact of the change in post operative follow up practice. * First draft of the workforce, training and recruitment plan will be complete by end June 2019. | | |

**John M Scott, Programme Director**

**Claire MacArthur, Programme Manager**

**18 June 2019**